S&P Futures
6,013.00 +26.00 (+0.43%) Dow Futures
44,644.00 +249.00 (+0.56%) Nasdaq Futures
20,955.25 +105.50 (+0.51%) Russell 2000 Futures
2,436.60 +23.00 (+0.95%) Crude Oil
71.02 -0.22 (-0.31%) Gold
2,677.80 -34.40 (-1.27%)
After hours:
| Previous Close | 2.4500 |
| Open | 2.4600 |
| Bid | 2.4200 x 900 |
| Ask | 2.7000 x 900 |
| Day's Range | 2.4846 - 2.8200 |
| 52 Week Range | 1.0200 - 6.2000 |
| Volume | |
| Avg. Volume | 126,990 |
| Market Cap | 24.155M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | Feb 07, 2025 - Feb 11, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.30 |
GlobeNewswireiBio Reports Fiscal First Quarter 2025 Financial Results
Advanced myostatin program with dosing underway in non-human primate studySAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progre
- GlobeNewswire
iBio and AstralBio Provide Update on Myostatin Program for Obesity
Lead molecule identified with potential extended half-life and subcutaneous dosingSAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Follo
